Purple BiotechPPBT +1.19%25 EV-to-FCF is -0.00 as of Jun. 29, 2026. GuruFocus rates PPBT with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 336 Biotechnology companies, Purple Biotech ranks better than 98.81% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Purple Biotech's Enterprise Value is $0.02 Mil.
Purple Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.80 Mil. Therefore, Purple Biotech's EV-to-FCF for today is -0.00.
The historical rank and industry rank for Purple Biotech's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of Purple Biotech was 0.04. The lowest was -0.01. And the median was 0.00.
PPBT's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 14.885 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Purple Biotech's PE Ratio (TTM) for today is calculated as:
Purple Biotech's share price for today is $1.70.
Purple Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-386.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Purple Biotech EV-to-FCF Related Terms
Purple Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Purple Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Purple Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Purple Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Purple Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Purple Biotech's EV-to-FCF falls into.
Purple Biotech's current Enterprise Value is $0.02 Mil.
Purple Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Purple Biotech (PPBT) has a EV-to-FCF of -0.00 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Purple Biotech and its competitors. According to the industry distribution chart, Purple Biotech ranks #4 out of 336 companies in the Biotechnology industry, placing it in the top 1.2%.
Is Purple Biotech's EV-to-FCF too high?
Purple Biotech's current EV-to-FCF is -0.00. Based on the distribution chart, Purple Biotech ranks #4 out of 336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Purple Biotech has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Purple Biotech ranks #4 out of 336 companies for EV-to-FCF. This places Purple Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Purple Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Purple Biotech's current EV-to-FCF is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (PPBT) has a current EV-to-FCF of -0.00. The current EV-to-FCF is -0.00. Purple Biotech's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Purple Biotech (PPBT), the current EV-to-FCF is -0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
25GF Score
Get the complete analysis for PPBT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPBT has been successfully added to your 
